Cardiac mortality · adults undergoing non‐cardiac surgery
1 finding from 1 review
Myocardial infarction (within 30‐days after surgery: as detected on an electrocardiogram or trans‐oesophageal echocardiogram) · adults undergoing non‐cardiac surgery
1 finding from 1 review
Acute stroke (within 30‐days after surgery: new focal neurologic deficit with signs and symptoms lasting longer than 24 hours) · adults undergoing non‐cardiac surgery
1 finding from 1 review
All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in all‐cause mortality (within 30‐days after surgery: any reported death) compared with control (moderate certainty).
1 finding from 1 review
Cardiac mortality · adults undergoing cardiac surgery
1 finding from 1 review
Myocardial infarction (within 30‐days after surgery: sudden death or death resulting from a primarily identifiable cardiac cause) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in myocardial infarction (within 30‐days after surgery: sudden death or… compared with control (moderate certainty).
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Control of epistaxis: episodes of re‐bleeding over 10 days All treatments (topical and oral) · adults with nasal haemorrhage (epistaxis)
Tranexamic acid probably leads to lower control of epistaxis: episodes of re‐bleeding over 10 days All… compared with placebo plus usual care or usual care alone (moderate certainty).
1 finding from 1 review
Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days · adults with nasal haemorrhage (epistaxis)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Control of epistaxis: episodes of re‐bleeding over 10 days Oral treatment only · adults with nasal haemorrhage (epistaxis)
Tranexamic acid probably leads to lower control of epistaxis: episodes of re‐bleeding over 10 days Oral… compared with placebo plus usual care or usual care alone (moderate certainty).
1 finding from 1 review
Control of epistaxis: episodes of re‐bleeding over 10 days Topical application (10% gel) only · adults with nasal haemorrhage (epistaxis)
Tranexamic acid showed no clear difference in control of epistaxis: episodes of re‐bleeding over 10 days Topical… compared with placebo plus usual care or usual care alone (low certainty).
1 finding from 1 review
Severity of re‐bleeding: proportion of patients requiring blood transfusion within 10 days · adults with nasal haemorrhage (epistaxis)
Tranexamic acid showed no clear difference in severity of re‐bleeding: proportion of patients requiring blood… compared with placebo plus usual care or usual care alone (low certainty).
1 finding from 1 review
Control of epistaxis: episodes of re‐bleeding over 10 days · adults with nasal haemorrhage (epistaxis)
1 finding from 1 review
no estimate extracted
10 participants
GRADE not reported
All‐cause mortality (30 days)—cardiac surgery · patients with coronary heart disease and/or valvular heart disease
Beta‐blocker showed no clear difference in all‐cause mortality (30 days)—cardiac surgery compared with control—cardiac surgery (moderate certainty).
1 finding from 1 review
All‐cause mortality (30 days)—non‐cardiac surgery · patients with conditions requiring non‐cardiac surgery
Beta‐blocker showed no clear difference in all‐cause mortality (30 days)—non‐cardiac surgery compared with control—non‐cardiac surgery (low certainty).
1 finding from 1 review